NCT00002129View on ClinicalTrials.gov

A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Vesnarinone

Trial Locations (1)

900121973

UCLA School of Medicine, Los Angeles

Sponsors
All Listed Sponsors
lead

Otsuka America Pharmaceutical

INDUSTRY

NCT00002129 - A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3 | Biotech Hunter | Biotech Hunter